COST EFFECTIVENESS ANALYSIS OF VACCINATION WITH 13-VALENT (PCV13) AND 23-VALENT (PPSV23) PNEUMOCOCCAL VACCINES FOR ADULTS IN COLOMBIA

被引：1
|
作者：
Nunez, S. M. [1 ]
Mould-Quevedo, J. F. [2 ]
Gutierrez-Ardila, M., V [1 ]
Roberts, C. S. [2 ]
La Rotta, J. E. [1 ]
机构：
[1] Pfizer Colombia, Bogota, Cundinamarca, Colombia
[2] Pfizer Inc, New York, NY USA
来源：
VALUE IN HEALTH | 2012年 / 15卷 / 04期
关键词：
D O I：
10.1016/j.jval.2012.03.1304
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
引用
收藏
页码：A242 / A242
页数：1
相关论文
共 50 条
  • [21] 13-valent pneumococcal conjugate vaccine (PCV13) is immunogenic and safe in children 6-17 years of age with sickle cell disease previously vaccinated with 23-valent pneumococcal polysaccharide vaccine (PPSV23): Results of a phase 3 study
    De Montalembert, Mariane
    Abboud, Miguel R.
    Fiquet, Anne
    Inati, Adlette
    Lebensburger, Jeffrey D.
    Kaddah, Normeen
    Mokhtar, Galila
    Piga, Antonio
    Halasa, Natasha
    Inusa, Baba
    Rees, David C.
    Heath, Paul T.
    Telfer, Paul
    Driscoll, Catherine
    Al Hajjar, Sami
    Tozzi, Alberto
    Jiang, Qin
    Emini, Emilio A.
    Gruber, William C.
    Gurtman, Alejandra
    Scott, Daniel A.
    PEDIATRIC BLOOD & CANCER, 2015, 62 (08) : 1427 - 1436
  • [22] The Serological Response Of Asthmatics To The 23-Valent Pneumococcal Polysaccharide Vaccine (ppsv23)
    Laratta, C. R.
    Williams, K.
    Vethanayagam, D.
    Ulanova, M.
    Vliagoftis, H.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2016, 193
  • [23] 13-valent pneumococcal conjugate vaccine (PCV13)
    Jefferies, Johanna M. C.
    Macdonald, Emily
    Faust, Saul N.
    Clarke, Stuart C.
    HUMAN VACCINES, 2011, 7 (10): : 1012 - 1018
  • [24] COST-UTILITY ANALYSIS OF PCV13 VERSUS PPSV23 IN ADULTS 65 AND MORE
    Biagini Leandro, L.
    Rojas Ruben, R.
    Fuentealba Francisca, F.
    Pezzani Marcela, M.
    VALUE IN HEALTH, 2015, 18 (07) : A806 - A806
  • [25] PHARMACOECONOMIC EVALUATION OF 13-VALENT PNEUMOCOCCAL CONJUGATE AND 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE IN CANADIAN ADULTS
    Chuck, A.
    Waye, A.
    Zanotti, G.
    Jacobs, P.
    Kellner, J.
    Tyrrell, G.
    VALUE IN HEALTH, 2012, 15 (04) : A243 - A243
  • [26] Cost-effectiveness of 13-valent pneumococcal conjugate vaccine (PCV13) in older Australians
    Dirmesropian, S.
    Wood, J. G.
    MacIntyre, C. R.
    Beutels, P.
    McIntyre, P.
    Menzies, R.
    Reyes, J. F.
    Chen, C.
    Newall, A. T.
    VACCINE, 2017, 35 (34) : 4307 - 4314
  • [27] Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients
    Kiyoshi Migita
    Yukihiro Akeda
    Manabu Akazawa
    Shigeto Tohma
    Fuminori Hirano
    Haruko Ideguchi
    Hideko Kozuru
    Yuka Jiuchi
    Ryutaro Matsumura
    Eiichi Suematsu
    Tomoya Miyamura
    Shunsuke Mori
    Takahiro Fukui
    Yasumori Izumi
    Nozomi Iwanaga
    Hiroshi Tsutani
    Kouichirou Saisyo
    Takao Yamanaka
    Shiro Ohshima
    Naoya Mori
    Akinori Matsumori
    Koichiro Takahi
    Shigeru Yoshizawa
    Yojiro Kawabe
    Yasuo Suenaga
    Tetsuo Ozawa
    Norikazu Hamada
    Yasuhiro Komiya
    Toshihiro Matsui
    Hiroshi Furukawa
    Kazunori Oishi
    Arthritis Research & Therapy, 17
  • [28] Effect of abatacept on the immunogenicity of 23-valent pneumococcal polysaccharide vaccination (PPSV23) in rheumatoid arthritis patients
    Migita, Kiyoshi
    Akeda, Yukihiro
    Akazawa, Manabu
    Tohma, Shigeto
    Hirano, Fuminori
    Ideguchi, Haruko
    Kozuru, Hideko
    Jiuchi, Yuka
    Matsumura, Ryutaro
    Suematsu, Eiichi
    Miyamura, Tomoya
    Mori, Shunsuke
    Fukui, Takahiro
    Izumi, Yasumori
    Iwanaga, Nozomi
    Tsutani, Hiroshi
    Saisyo, Kouichirou
    Yamanaka, Takao
    Ohshima, Shiro
    Mori, Naoya
    Matsumori, Akinori
    Takahi, Koichiro
    Yoshizawa, Shigeru
    Kawabe, Yojiro
    Suenaga, Yasuo
    Ozawa, Tetsuo
    Hamada, Norikazu
    Komiya, Yasuhiro
    Matsui, Toshihiro
    Furukawa, Hiroshi
    Oishi, Kazunori
    ARTHRITIS RESEARCH & THERAPY, 2015, 17
  • [29] MODELLING BUDGET IMPACT (BI) OF VACCINATING AT-RISK ADULTS AND THE ELDERLY WITH 23-VALENT PNEUMOCOCCAL POLYSACCHARIDE VACCINE (PPV23) COMPARED TO 13-VALENT PNEUMOCOCCAL CONJUGATE VACCINE (PCV13) IN GERMANY
    Jiang, Y.
    Gauthier, A.
    Annemans, L.
    van der Linden, M.
    Nicolas-Spony, L.
    Bresse, X.
    VALUE IN HEALTH, 2011, 14 (07) : A268 - A268
  • [30] The cost-effectiveness of using pneumococcal conjugate vaccine (PCV13) versus pneumococcal polysaccharide vaccine (PPSV23), in South African adults
    Feldman, Charles
    Dlamini, Sipho K.
    Madhi, Shabir A.
    Meiring, Susan
    von Gottberg, Anne
    de Beer, Janetta C.
    de Necker, Margreet
    Stander, Marthinus P.
    PLOS ONE, 2020, 15 (01):
12345